Soluble CD26 / Dipeptidyl Peptidase IV Enhances Human Lymphocyte Proliferation In Vitro Independent of Dipeptidyl Peptidase Enzyme Activity and Adenosine Deaminase Binding

Scandinavian Journal of Immunology

Volumn 73, Issue 2, 2011, Pages 102-111

  Yu, D M T ^a   Slaitini, L ^a   Gysbers, V ^a   Riekhoff, A G M ^a   Kahne T ^b   Knott, H M ^a   De Meester, I ^c   Abbott, C A ^a,d   McCaughan, G W ^a   Gorrell, M D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; DIPEPTIDYL PEPTIDASE IV; OKT 3; PHYTOHEMAGGLUTININ; VIRUS ANTIGEN;

APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROTECTION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

ADENOSINE DEAMINASE; ADULT; CELL PROLIFERATION; CELLS, CULTURED; DIPEPTIDYL PEPTIDASE 4; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MIDDLE AGED; PROTEIN BINDING; SOLUBILITY; YOUNG ADULT;

EID: 78650799604     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02488.x     Document Type: Article

References (56)

1. Gorrell MD, Gysbers V, McCaughan GW. CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001;54:249-64.
2. Yu DMT, Ajami K, Gall MG et al. The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem 2009;57:1025-40.
3. De Meester IA, Kestens LL, Vanham GL et al. Costimulation of CD4+ and CD8+ T cells through CD26: the ADA-binding epitope is not essential for complete signaling. J Leukoc Biol 1995;58:325-30.
4. Gorrell MD, Wickson J, McCaughan GW. Expression of the rat CD26 antigen (dipeptidyl peptidase IV) on subpopulations of rat lymphocytes. Cell Immunol 1991;134:205-15.
5. Kähne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth. Int J Mol Med 1999;4:3-15.
6. De Meester I, Scharpé S, Vanham G et al. Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster. Immunobiology 1993;188:145-58.
7. Ibegbu CC, Xu Y-X, Fillos D, Radziewicz H, Grakoui A, Kourtis AP. Differential expression of CD26 on virus-specific CD8+ T cells during active, latent and resolved infection. Immunology 2009;126:346-53.
8. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008;29:295-301.
9. Yu DMT, Yao T-W, Chowdhury S et al. The Dipeptidyl Peptidase IV family in cancer and cell biology. FEBS J 2010;277:1126-44.
10. De Meester I, Vanham G, Kestens L et al. Binding of adenosine deaminase to the lymphocyte surface via CD26. Eur J Immunol 1994;24:566-70.
11. Lambeir A-M, Durinx C, Scharpé S, De Meester I. Dipeptidyl peptidase IV from bench to bedside: An update on structural properties, functions and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.
12. Martin M, Huguet J, Centelles JJ, Franco R. Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. J Immunol 1995;155:4630-43.
13. Hegen M, Kameoka J, Dong RP, Schlossman SF, Morimoto C. Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology 1997;90:257-64.
14. Cordero OJ, Salgado FJ, Fernandez-Alonso CM et al. Cytokines regulate membrane adenosine deaminase on human activated lymphocytes. J Leukoc Biol 2001;70:920-30.
15. Dong RP, Tachibana K, Hegen M et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997;159:6070-6.
16. Lankas G, Leiting B, Roy R et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94.
17. Vora KA, Porter G, Peng R et al. Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol 2009;10:19.
18. Abbott CA, McCaughan GW, Levy MT, Church WB, Gorrell MD. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain. Eur J Biochem 1999;266:798-810.
19. Gorrell MD. First bite. Nat Struct Biol 2003;10:3-5.
20. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human DPP-IV/CD26 in complex with a substrate analogue. Nat Struct Biol 2003;10:19-25.
21. Weihofen WA, Liu J, Reutter W, Saenger W, Fan H. Crystal structure of CD26/Dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J Biol Chem 2004;41:43330-5.
22. Durinx C, Lambeir AM, Bosmans E et al. Molecular characterization of dipeptidyl peptidase activity in serum - soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000;267:5608-13.
23. Tanaka T, Duke-Cohan JS, Kameoka J et al. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci U S A 1994;91:3082-6.
24. Schmitz T, Underwood R, Khiroya R, Bachovchin WW, Huber BT. Potentiation of the immune response in HIV-1(+) individuals. J Clin Invest 1996;97:1545-9.
25. Hühn J, Ehrlich S, Fleischer B, von Bonin A. Molecular analysis of CD26-mediated signal transduction in T cells. Immunol Lett 2000;72:127-32.
26. Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci U S A 1993;90:4586-90.
27. Ohnuma K, Munakata Y, Ishii T et al. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J Immunol 2001;167:6745-55.
28. Abbott CA, McCaughan GW, Gorrell MD. Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett 1999;458:278-84.
29. Ajami K, Abbott CA, Obradovic M et al. Structural requirements for catalysis, expression and dimerisation in the CD26/DPIV gene family. Biochemistry 2003;42:694-701.
30. Oravecz T, Pall M, Roderiquez G et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation normal T cell expressed and activated) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997;186:1865-72.
31. De Meester I, Vanhoof G, Lambeir AM, Scharpé S. Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26 dipeptidyl peptidase IV (EC 3.4.14.5). J Immunol Methods 1996;189:99-105.
32. Morimoto C, Torimoto Y, Levinson G et al. 1F7, a novel cell surface molecule involved in helper function of CD4 cells. J Immunol 1989;143:3430-5.
33. Nagatsu T, Hino M, Fuyamada H. New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase. Anal Biochem 1976;74:466-76.
34. Yu DMT, Wang XM, McCaughan GW, Gorrell MD. Extra-enzymatic functions of the dipeptidyl peptidase (DP) IV related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. FEBS J 2006;273:2447-61.
35. Kähne T, Kroning H, Thiel U, Ulmer AJ, Flad HD, Ansorge S. Alterations in structure and cellular localization of molecular forms of DP IV/CD26 during T cell activation. Cell Immunol 1996;170:63-70.
36. Chien C-H, Huang L-H, Chou C-Y et al. One site mutation disrupts dimer formation in human DPP-IV proteins. J Biol Chem 2004;279:52338-45.
37. DukeCohan JS, Morimoto C, Rocker JA, Schlossman SF. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T Cells. J Immunol 1996;156:1714-21.
38. Engel M, Hoffmann T, Wagner L et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A 2003;100:5063-8.
39. Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpé S, De Meester I. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 2001;39:155-9.
40. Carr RD, Larsen MO, Jelic K et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 2010;95:872-8.
41. Andrieu T, Thibault V, Malet I et al. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J Clin Virol 2003;27:59-68.
42. Itou M, Kawaguchi T, Taniguchi E et al. Altered expression of glucagon-like peptide and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J Gastroenterol Hepatol 2008;23:244-51.
43. Hegen M, Mittrucker HW, Hug R et al. Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells. Immunobiology 1993;189:483-93.
44. Steeg C, Hartwig U, Fleischer B. Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity. Cell Immunol 1995;164:311-5.
45. Abbott CA, Yu DMT, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000;267:6140-50.
46. Ajami K, Abbott CA, McCaughan GW, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 2004;1679:18-28.
47. Schön E, Demuth HU, Eichmann E et al. Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV. Scand J Immunol 1989;29:127-32.
48. Kähne T, Neubert K, Ansorge S. Enzymatic activity of DPIV/CD26 is involved in PMA-induced hyperphosphorylation of p56(lck). Immunol Lett 1995;46:189-93.
49. Reinhold D, Bank U, Bühling F et al. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production. Immunobiology 1993;188:403-14.
50. Reinhold D, Goihl A, Wrenger S et al. Role of dipeptidyl peptidase IV (DPIV)-like enzymes in T lymphocyte activation: investigations in DPIV/CD26 knockout mice. Clin Chem Lab Med 2009;47:268-74.
51. Kim SJ, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 2009;58:641-51.
52. Dang NH, Torimoto Y, Sugita K et al. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol 1990;145:3963-71.
53. Vanham G, Kestens L, De Meester I et al. Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J Acquir Immune Defic Syndr 1993;6:749-57.
54. Dourado M, Sarmento AB, Pereira SV et al. CD26/DPPIV expression and 8-azaguanine response in T-acute lymphoblastic leukaemia cell lines in culture. Pathophysiology 2007;14:3-10.
55. Muscat C, Bertotto A, Agea E et al. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol 1994;98:252-6.
56. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 2005;108:277-92.